| Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study C Berthon, E Raffoux, X Thomas, N Vey, C Gomez-Roca, K Yee, ... The Lancet Haematology 3 (4), e186-e195, 2016 | 446 | 2016 |
| Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study S Amorim, A Stathis, M Gleeson, S Iyengar, V Magarotto, X Leleu, ... The Lancet Haematology 3 (4), e196-e204, 2016 | 417 | 2016 |
| Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports E Wasserman, A Myara, F Lokiec, F Goldwasser, F Trivin, M Mahjoubi, ... Annals of Oncology 8 (10), 1049-1051, 1997 | 267 | 1997 |
| Population pharmacokinetics of total and unbound plasma cisplatin in adult patients S Urien, F Lokiec British journal of clinical pharmacology 57 (6), 756-763, 2004 | 178 | 2004 |
| Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics E Wasserman, C Cuvier, F Lokiec, F Goldwasser, S Kalla, ... Journal of clinical oncology 17 (6), 1751-1751, 1999 | 177 | 1999 |
| Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. LP Rivory, MC Haaz, P Canal, F Lokiec, JP Armand, J Robert Clinical cancer research: an official journal of the American Association …, 1997 | 177 | 1997 |
| OTX015 (MK‐8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models C Berenguer‐Daizé, L Astorgues‐Xerri, E Odore, M Cayol, E Cvitkovic, ... International journal of cancer 139 (9), 2047-2055, 2016 | 137 | 2016 |
| Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European … P Canal, C Gay, A Dezeuze, JY Douillard, R Bugat, R Brunet, A Adenis, ... Journal of clinical oncology 14 (10), 2688-2695, 1996 | 137 | 1996 |
| Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine A Mallet, F Mentré, JL Steimer, F Lokiec Journal of Pharmacokinetics and Biopharmaceutics 16, 311-327, 1988 | 133 | 1988 |
| Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines N Aissat, C Le Tourneau, A Ghoul, M Serova, I Bieche, F Lokiec, ... Cancer chemotherapy and pharmacology 62, 305-313, 2008 | 120 | 2008 |
| Phase I–II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma S Faivre, T Le Chevalier, C Monnerat, F Lokiec, S Novello, J Taieb, ... Annals of oncology 13 (9), 1479-1489, 2002 | 115 | 2002 |
| Phase I population pharmacokinetic assessment of the oral bromodomain inhibitor OTX015 in patients with haematologic malignancies E Odore, F Lokiec, E Cvitkovic, M Bekradda, P Herait, F Bourdel, C Kahatt, ... Clinical pharmacokinetics 55, 397-405, 2016 | 100 | 2016 |
| Preclinical and clinical development of novel agents that target the protein kinase C family M Serova, A Ghoul, KA Benhadji, E Cvitkovic, S Faivre, F Calvo, F Lokiec, ... Seminars in oncology 33 (4), 466-478, 2006 | 97 | 2006 |
| Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis M Tod, F Lokiec, R Bidault, F De Bony, O Petitjean, Y Aujard, ... Antimicrobial agents and chemotherapy 45 (1), 150-157, 2001 | 96 | 2001 |
| Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine F Lokiec, P Canal, C Gay, E Chatelut, JP Armand, H Roché, R Bugat, ... Cancer chemotherapy and pharmacology 36, 79-82, 1995 | 88 | 1995 |
| Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells M Serova, A Ghoul, KA Benhadji, S Faivre, C Le Tourneau, E Cvitkovic, ... Molecular cancer therapeutics 7 (4), 915-922, 2008 | 78 | 2008 |
| Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography MF Pichon, F Cvitkovic, K Hacene, J Delaunay, F Lokiec, ... In vivo 19 (3), 567-576, 2005 | 78 | 2005 |
| Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients S Urien, E Brain, R Bugat, X Pivot, I Lochon, MLV Van, F Vauzelle, ... Cancer chemotherapy and pharmacology 55, 55-60, 2005 | 78 | 2005 |
| Irinotecan (CPT-11) metabolites in human bile and urine. F Lokiec, BM du Sorbier, GJ Sanderink Clinical cancer research: an official journal of the American Association …, 1996 | 72 | 1996 |
| Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule D Khayat, F Lokiec, JP Bizzari, M Weil, L Meeus, M Sellami, J Rouesse, ... Cancer research 47 (24_Part_1), 6782-6785, 1987 | 71 | 1987 |
